Targeted PI3K inhibitors include alpelisib (BYL719), taselisib (GDC‐0032), and inavolisib (GDC‐0077), and alpelisib is the first oral PI3K inhibitor specifically targeting the p110α subtype that has been approved for the treatment of breast cancer [5]. This evidence concerns the gene PIK3CG and breast carcinoma.